Research & Preclinical Development

We Want More for Patients. A World Without Cancer.

February 04, 2025

On World Cancer Day, we’re motivated by the potential for more.

By: Regeneron Editorial

Every discovery in cancer care means the potential for more hope, more breakthroughs and more lives impacted. At Regeneron, we’re committed to pursuing more. We strive to ignite hope by advancing research in a number of solid tumors and blood cancers, backed by our unique ability to translate science into medicine. Our oncology strategy is powered by novel approaches that allow us to accelerate the way medicines are traditionally discovered and developed.

The potential for more motivates us every day — more innovation leading to more treatments in development. We face cancer head-on because we want more for patients. At Regeneron, we move science to medicine because people with cancer are meant for more.

Headshot of Israel Lowy, MD, PhD.

“I am hopeful that Regeneron will be a leading contributor to a world in which when patients hear the diagnosis of cancer, they are not struck with fear of a death sentence, but understand that there are therapies available, hopefully many of them contributed by Regeneron, that can help them manage this disease in a way that allows them to go on with their lives, be with their families and not have cancer define the rest of their life.”

Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology

Headshot of Andres Sirulnik, MD, PhD.

"This World Cancer Day, I am reflecting on the incredible progress we have made to advance our understanding and advance research for patients. Our aim for this and every year is to continue to deliver transformative science to drive meaningful impact for blood cancer patients who need it most."

Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology

Headshot of Justin Holko.

“World Cancer Day allows us to reflect on how far the industry has come over the years. I’m inspired by the progress and excited about the opportunity we have to benefit more patients as the science continues to evolve. At Regeneron, we have a relentless focus on the science — and as a team, we come to work every day motivated to turn our problem solving and cutting-edge science into innovative breakthroughs in cancer care so we can deliver treatments that address patient needs.”

Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit